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PDA IRELAND SYMPOSIUM
EMBRACING THE CHALLENGES OF
LIFECYCLE BASED VALIDATION
Overview of the
FDA PV Guidance
Nuala Calnan
Regulatory Science Researcher
School of Chemical & Pharmaceutical Sciences
DIT, Kevin St.
The PSRT at DIT is engaged in Regulatory Science
research into the development of implementation and
technology solutions for the pharmaceutical
manufacturing industry to enable those involved in the
manufacture of drug products to meet the expectations
of the international pharmaceutical regulatory
community.
The PSRT actively engages with industry and
regulators to focus on addressing the challenges and
opportunities of implementing Science and Risk based
manufacturing approaches.
See: http://www.dit.ie/chemistry/research/psrt/
Current Regulatory Science Research
• Quality Risk Management (QRM) Toolset
• Research on impact of Uncertainty and
Subjectivity in the assessment of risks to quality
• Process Analytical Technology (PAT) R&D on
imaging technologies for use in blending,
granulation, roller compaction/milling,
compression and packaging processes
• Development of a ICH Q8,9,10 Implementation
Methodology and Lean Six Sigma Toolset
• Research on Knowledge Management tools for
capturing, generating and enhancing scientific
knowledge
• Research on impact of new US & EU regulations
on Process Validation (PV) for pharmaceutical
manufacturers
Ian Jones
Nuala Calnan
Dr. Alice Redmond
Dr. Kevin O’ Donnell
Dr. Anne Greene
School of Chemical &
Pharmaceutical Science
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Process Validation:
Some
Fundamentals
Key Publications
Nov 2005 & Nov 2008
20122006 2007 2008 2009 2010 20112003 2004 2005
Nov: Q8 Published
Q9 Published
Q10 Concept Document
Nov: Implementation
Working Group for Q8,9,10
Concept Document published
Aug: Q8(R2)
Published
Jan: FDA PV Guidance
issued
Dec: Q8,9,10
Points to Consider PtC(R2)
Published
Ongoing
engagement
through
International
Conferences
Nov :
•Q8,9,10 Q&A (R4)
Published
•ICH Q-IWG Integrated
Training Programme
published online
Jun: Q10 Published
Jul: New Quality Paradigm
Oct: Q8 Concept Document
Nov: Q9 Concept Document
Mar: EU
PV Draft
guide
issued
May: Q11
Published
Timeline
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1.
2.
3.
FDA’s Guidance for Industry on Process
Validation has been welcomed for;
The clarity of its
integrated 3 stage
lifecycle process
The elimination of the
‘3 Golden Batches’
concept.
Its emphasis on the
need for effective
scientific knowledge
led programs
Process Validation is establishing
documented evidence which
provides a high degree of
assurance that a specific process
will consistently produce a
product meeting its pre-
determined specifications and
quality characteristics
“process validation is defined as
the collection and evaluation of
data, from the process design
stage throughout production,
which establishes scientific
evidence that a process is
capable of consistently
delivering quality products.”
2011
1987
Process Validation -Shift in Emphasis over 25 years?
In
Scope
Human
Drugs
Veterinary
Drugs
API‘s
Biological’s
What’s in Scope?
Drug element
of a
Combination Product
Out of
Scope
Investigational
Medicinal
Products *
Medical
Devices
What’s out of Scope?
* See Note 3 : Page 2 Commercial Manufacturing processes do not include Clinical or treatment IND materials
Type A
Medicated
Articles
/ Feeds
Dietary
Supplements
Human
Tissue
Cl
ick
 to
 bu
y N
OW
!
PD
F-XChange
w
ww.docu-track
.co
m C
lic
k t
o b
uy
 N
OW
!
PD
F-XChange
w
ww.docu-track
.co
m
25/07/2013
4
Where are the Challenges?
• Science and Risk based PV/PPQ requires product and
process understanding, good science, statistical
confidence
– Statistically based sampling plans and acceptance criteria
– Determination of the number of PPQ/PV batches
• Acceptance criteria across batches
• Validation level sampling and testing beyond PV
exercise
• Decision to release PV/PPQ batches based on stage 1
and stage 2 criteria
• Application across broad spectrum
13
“Effective Process Validation contributes significantly to
assuring drug quality”
Basic Principles of Quality Assurance
A drug should be produced that is fit for its intended use;
• Quality, safety, and efficacy are designed or built into the
product
• Quality cannot be adequately assured merely by in-
process and finished-product inspection or testing
• Each step of a manufacturing process is controlled to
assure that the finished product meets all quality
attributes including specifications
Ref : Guidance for Industry Process Validation: General Principles and Practices (Nov 2008)
FDA encourages the use of;
Modern Pharmaceutical
Development concepts
Quality Risk
Management
Quality Systems
at all stages of the
manufacturing
process lifecycle
Product Lifecycle
Approach
The guidance supports process improvement and innovation through sound science
Validation of the process is not
a ‘one off’ event but represents
an ongoing continuum of
scientific knowledge
development and ongoing
assurance.
Ongoing Continuum….
“Knowledge gained from
development is the foundation for
process validation”
ICH-IWG Point to Consider Document
Dec 2012
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Key to this success
0
50
100
150
200
250
2004 2005 2006 2007 2008 2009 2010
Description A Description B Description C
25
30
2512
55
Description A Description B
Description C Description D
Description E
60%
30%
10% Description C
Description B
Description A
100%
5 7
2
4
2
3
7
9
5
6
8
6
5
3
Company A Company B
‘Proficiency in the collection and
evaluation of information and data
about the performance of the
process’
Process Validation:
Interpretation
the Guidance
Understanding the nuances…
One important point of distinction between the PV guides is that they
are written to address different purposes;
• The FDA guidance outlines principles and approaches
manufacturers can use to validate the commercial manufacturing
processes for drug products
• The EU draft PV guideline provides information relating to process
validation that should to be considered as part of the dossier
submission, when applying for a Marketing Authorisation and as
such is mainly aimed at the pharmaceutical assessors
• The proposed update to Annex 15 of the EU GMP Guide:
Qualification and Validation will contain the details associated with
the actual qualification and validation studies undertaken at
commercial scale prior to release of product into the marketplace.
Draft EU considers 3
possible PV approaches a
company may consider
when planning a PV
program;
• A Traditional Process
Validation Approach
• A Continuous Process
Verification (CPV)
Approach
• A Hybrid Approach
US FDA guide outlines a
structured 3 Stage
approach;
• Stage 1 - Process Design
• Stage 2 - Process
Qualification
• Stage 3 - Continued
Process Verification
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Both US and EU guides emphasize the
importance of the links between;
Product and process
design and
development
Qualification of the
commercial
manufacturing
process
Maintenance of the
process in a state of
control during routine
commercial production
Product Lifecycle
Approach
Knowledge is the key…
• Both EU and US guidelines note that the
success of the validation program will hinge
upon the quality and depth of the product
and process understanding gained, largely
during the development phases of the
lifecycle.
• The importance of utilising the knowledge
gained through the application of scientific
approaches (ICH Q8) and quality risk
management (ICH Q9) to the development
of a product and its manufacturing process is
emphasized.
Understanding Variation
The FDA guide gives specific
recommendations on using
this knowledge to:
• Understand the sources of
variation within the process
• Detect the presence and
degree of variation
• Understand the impact that
variation has on the process
and ultimately on the
product attributes
Importance of being able to
demonstrate control of the variation
in a manner commensurate with the
risk it represents to the process and
product.
General Considerations for PV
Importance of making the entire process validation
program more effective and efficient
• Good project management
• Robust scientific knowledge collection, management and
archiving
• Uniform collection and assessment of information methods
• Reducing the burden of redundant information gathering
• Use of an integrated team approach
• Appropriately documented and planned studies
• All attributes and parameters should be evaluated and
reevaluated as new information arises
• Criticality should be viewed as a continuum rather than  binary
• Statistical assessment of data capability
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Stage 1 – Process Design: The commercial process is
defined during this stage based on knowledge gained
through development and scale-up activities
Stage 2 – Process Qualification: During this stage,
the process design is confirmed as being capable of
reproducible commercial manufacturing
Stage 3 – Continued Process Verification: Ongoing
assurance is gained during routine production that the
process remains in a state of control
3 Stages of Process Validation
1.
2.
3.
Stage 1 – Process Design
Design a process suitable for routine commercial manufacturing that
can consistently deliver a product that meets its quality attributes
a. Building and Capturing Process Knowledge and
Understanding
b. Establishing a Strategy for Process Control
Stage 2 – Process Qualification
Process design is evaluated if it is capable of reproducible commercial manufacturing
1. Design of a Facility and Qualification of Utilities and
Equipment
2. Process Performance Qualification (PPQ)
3. PPQ Protocol
4. Protocol Execution and Report
Role of QA
Approved for Commercial Distribution
Batch
C
Batch B
Batch
A
The decision to begin
commercial distribution
should be supported by data
from stage 1 and stage 2
Released
Product and
Continued
Process
Verification
Facility and
Equipment
'Qualified‘
How Many ?
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Approved for Commercial Distribution
Batch
C
Batch B
The decision to begin
commercial distribution should
be supported by data from
commercial batches.
Released
Product and
Continued
Process
Verification
Facility and
Equipment
'Qualified‘
How Many ?
Approved for Commercial Distribution
Batch B
The decision to begin
commercial distribution should
be supported by data from
commercial batches.
Released
Product and
Continued
Process
Verification
Facility and
Equipment
'Qualified‘
How Many ?
Stage 3 – Continued Process Verification
Continually assure that the process remains in a state of control (the validated state)
during commercial manufacture
• Detection of Process Drift
• Ongoing program to collect and analyze product and
process data that relate to product quality
• Statistician led analysis
• Detection, control, and/or mitigation strategies
• Continued enhanced monitoring
• Process Optimization
• Maintenance
Success…
The success of the validation program will hinge on
the quality of the knowledge gained, developed and
enhanced.
• Knowledge gained in the product and process
development stage
• Knowledge developed during the validation
studies
• Knowledge enhance throughout the on- going
routine manufacture and distribution
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Alignment
34
Deming’s System of Profound Knowledge
Deming advocated that all managers need to have
what he called a System of Profound Knowledge,
consisting of four parts:
• Appreciation of a system: understanding the
overall processes involving suppliers, producers,
and customers (or recipients) of goods and
services
• Knowledge of variation: understanding the
range and causes of variation in quality
• Theory of knowledge: the concepts explaining
knowledge and the limits of what can be known
• Knowledge of psychology: understanding the
concepts of human nature.
Source: ISPE C&Q Seminar June 2008 Washington- Good Engineering Practice, Nuala Calnan
Effective Process
Validation
contributes
significantly to
assuring drug
quality
Source: Dr. K.O’Donnell, GMP & Market Compliance Info Day, September 2012
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IMB Analysis Serious Quality Defects
2004-2011
Source: Dr. K.O’Donnell, GMP & Market Compliance Info Day, September 2012
US FDA Recall Statistics
Dramatic increase of Class I recalls of
prescription drugs, which increased
by 100 % compared to the Q4
Q1 2013, 107 drug and pharmaceutical recalls,
an increase of 32 % from the previous quarter
and higher than the average number of events
last year.
FDA Commissioner Margaret A.
Hamburg quoted recently
Impact of Globalisation in supply*
• 40% of finished pharmaceuticals
• A staggering 80% of the active
ingredients used in the drugs
consumed in the US come from
abroad.
“Today we recognize that to
successfully protect U.S. public health,
we must think, act, and engage
globally. Our interests must be
broader than simply those within our
own borders."
*Weaving New Threads in FDA’s Global Safety Net. FDA: 22
Feb 2013.
Without product quality, none of us can
feel confident that the product will be
either safe or effective. These concepts
go hand and hand. And unfortunately,
we’ve seen far too many quality lapses
throughout the pharmaceutical
industry over the past few years. ...,
they are warning signals that we can
and must do more.
That’s why we’ve chosen to make
quality one of our highest priorities
this year and we’d like you to do the
same.”
Product Quality**
**Address to the Annual Meeting Generic
Pharmaceutical Manufacturers Association on
the Prioritization of Product Quality. FDA: Feb 22
2013.
Process Validation :
Examples of Deficiencies
1. Poor controls in place for the identification of CPPs
2. Poor linkages between risk assessment activities and PV
protocols
3. Insufficient extent of PV testing performed
4. Lack of good science when defining PV acceptance criteria
5. Poor critical evaluation of PV data
6. Lack of good science used in designing PV protocols
7. Insufficient sampling activities
8. Lack of review of validation status following the receipt of
important new data
9. Actual manufacturing processes not supported by PV data
10. Poor use of concurrent validation
Source: Dr. K.O’Donnell, GMP & Market Compliance Info Day, September 2012
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Questions and
Answers
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